We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Palforzia

News List

European Commission approves first treatment for peanut allergy europeanpharmaceuticalreview
January 06, 2021
Aimmune Therapeutics’ PALFORZIA® has been approved by the European Commission as a treatment for peanut allergy.
Aimmune’s peanut allergy med Palforzia wins EU approval pharmatimes
December 22, 2020
The European Commission (EC) has approved Aimmune Therapeutics’ Palforzia, making it the first treatment for peanut allergy in the EU, according to the firm.
Aimmune’s peanut allergy med moves toward EU approval pharmatimes
October 22, 2020
Aimmune has been granted a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its drug Palforzia as a treatment of peanut allergic patients aged 4-17 years.
Nestlé to acquire biopharma company, Aimmune Therapeutics expresspharma
September 01, 2020
Aimmune's Palforzia is an FDA-approved treatment to help reduce the frequency and severity of allergic reaction to peanuts.
FDA to Assess First Drug Meant to Prevent Peanut Allergy drugs
September 16, 2019
A panel of experts at the U.S. Food and Drug Administration is set to weigh the pros and cons of what could be the first drug ever approved to prevent peanut allergy.